BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.The analyst comments "Zymeworks (ZYME, Not Rated) has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades